Abstract
Systemic treatment, including monoclonal antibodies against tumor-associated targets, has increased the median survival of patients with metastatic colorectal cancer over 100% in the past few years. The prolonged life-span of these patients has led to the development of new and unusual complications that were typically not seen in the era of 5-fluorouracil and leucovorin. A multidisciplinary approach is now more crucial than ever. In this report, we will discuss a patient who presented with a metastatic lesion nearly obstructing the small bowel three years following the diagnosis of metastatic colon cancer.
Original language | English (US) |
---|---|
Pages (from-to) | S15-S18 |
Journal | Anti-Cancer Drugs |
Volume | 20 |
Issue number | SPEC. ISS. 2 |
DOIs | |
State | Published - May 2009 |
Keywords
- Avastin
- Multi-modality therapy
- XELIRI
ASJC Scopus subject areas
- Oncology
- Pharmacology
- Pharmacology (medical)
- Cancer Research